Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety, Tolerability and Efficacy of MB07133 Plus Sintilimab in Patients With Hepatocellular Carcinoma，a Phase 1/2a Study

NCT06141109 is registered in ClinicalTrials.gov with Xi'an Xintong Pharmaceutical Research Co.,Ltd. as lead sponsor.

NCT NCT06141109
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06141109 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety, Tolerability and Efficacy of MB07133 Plus Sintilimab in Patients With Hepatocellular Carcinoma，a Phase 1/2a Study
Lead sponsor
Xi'an Xintong Pharmaceutical Research Co.,Ltd.
Phase
Phase 1/2
Overall status
Unknown status
Start date
January 18, 2022
Completion date
December 31, 2025
Enrollment
39 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

efficacy, mtd, safety issues